AP
MDGL icon

AtonRa Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

AtonRa Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$794K Sell
3,433
-424
-11% -$74.2K 1.58% 9
2023
Q3 		$563K Sell
3,857
-901
-19% -$170K 1.18% 21
2023
Q2 		$1.1M Sell
4,758
-550
-10% -$149K 1.7% 10
2023
Q1 		$1.29M Sell
5,308
-398
-7% -$108K 1.88% 7
2022
Q4 		$1.66M Sell
5,706
-1,543
-21% -$151K 2.11% 4
2022
Q3 		$471K Sell
7,249
-35
-0.5% -$2.43K 0.46% 92
2022
Q2 		$521K Buy
+7,284
New +$535K 0.48% 98

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AtonRa Partners's MDGL Position: Q4 2023 in Review

AtonRa Partners reduced its Madrigal Pharmaceuticals (MDGL) stake by 11% in Q4 2023, selling an estimated $74.2K and leaving 3,433 shares worth $794K. The position accounts for 1.58% of the portfolio, ranked #9.

AtonRa Partners first reported a position in MDGL in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.66M in Q4 2022. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

  • AtonRa Partners held 3,433 shares of Madrigal Pharmaceuticals worth $794K as of Q4 2023.
  • AtonRa Partners sold 424 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $74.2K.
  • Madrigal Pharmaceuticals made up 1.58% of AtonRa Partners's portfolio in Q4 2023, its #9 holding.
  • AtonRa Partners first reported a position in Madrigal Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
  • AtonRa Partners's Madrigal Pharmaceuticals position peaked at $1.66M in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.